Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study

BACKGROUND/AIMS: Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior treatment failure. We investigated the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Jeong, Kim, Yoon Jun, Lee, Sung Wook, Lee, Youn-Jae, Yoon, Ki Tae, Byun, Kwan Soo, Jung, Yong Jin, Tak, Won Young, Jeong, Sook-Hyang, Kwon, Kyung Min, Suri, Vithika, Wu, Peiwen, Jang, Byoung Kuk, Lee, Byung Seok, Cho, Ju-Yeon, Jang, Jeong Won, Yang, Soo Hyun, Paik, Seung Woon, Kim, Hyung Joon, Kwon, Jung Hyun, Park, Neung Hwa, Kim, Ju Hyun, Kim, In Hee, Ahn, Sang Hoon, Lim, Young-Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338242/
https://www.ncbi.nlm.nih.gov/pubmed/37424500
http://dx.doi.org/10.3904/kjim.2022.252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338242/
https://www.ncbi.nlm.nih.gov/pubmed/37424500
http://dx.doi.org/10.3904/kjim.2022.252

Ejemplares similares